-
Report details
-
3
Figures
-
22
Tables
-
Chapter One: Executive Summary
-
Chapter 2: Introduction and Overview
-
Histology and Cytology
-
In Situ Hybridization (ISH)
-
Immunoassays
-
Polymerase Chain Reaction (PCR)
-
Companion Diagnostics
-
Predictive Biomarker Tests for Drug-Gene Match
-
DNA and RNA Variants
-
Molecular Diagnostics in Hereditary Cancer Diagnosis
-
Cancer Markers in Widespread Usage
-
Chapter 3: Market Trends
-
Growth in Precision Medicine, Companion Diagnostics, Related Applications
-
Pharmacodiagnostic Tests
-
Companies Offering Liquid Biopsy-based Molecular Cancer Assays
-
Liquid Biopsy-based Non-Invasive Cancer Molecular Diagnostics
-
Circulating Tumor Cell (CTC) Tests
-
Sample Collection Products
-
Exosome Sequencing
-
Next-Generation Sequencing Tests
-
Whole-Genome Sequencing
-
Exome Sequencing
-
RNA Sequencing
-
Regulatory Influences
-
Companies
-
Advanced Histology Techniques
-
Automation of Histology
-
Artificial Intelligence
-
Mass Spectrometry
-
Regulatory and Reimbursement Trends
-
Reimbursement Breakthroughs and Challenges
-
Next Generation Sequencing Coverage
-
Companion Diagnostics Seeing Development in Regulations
-
LDTs
-
Food and Drug Administration
-
Directive 98/79/EC
-
Health Canada Changes and Forecasted Action
-
International Growth Opportunities
-
Chapter 4: Market Revenues and Forecast
-
Molecular Cancer Test Regional Distribution
-
Histology and Cytology
-
Histology Regional Distribution
-
Molecular Cancer Diagnostics Segment by Technology/ Method
-
HPV Regional Distribution
-
Drivers and Challenges
-
Clinical Utility of Molecular Diagnostics
-
Technological Advancements Including NGS Adopted Incrementally
-
Chapter 5: Competitive Analysis
-
Immunoassay Competitive Trends
-
IHC Market
-
Competition in ISH
-
Molecular Cancer Diagnostics Landscape
-
HPV
-
Liquid Biopsy and CTCs
-
Recent Deals and Collaborations
-
Chapter 6: COVID-19 Impact
-
Minimal Ongoing Significant Disruptions
-
Chapter 7: Corporate Profiles
-
Abbott Diagnostics
-
Companion Testing
-
Liquid Biopsy
-
Agendia BV
-
Agilent Technologies
-
Agilent in Genomics
-
Cytogenetic Analysis
-
Sequencing
-
CRISPR
-
Flow Cytometry
-
Companion Diagnostics – Dako
-
ARUP Laboratories
-
Asuragen Inc.
-
Beckman Coulter (Danaher)
-
Immunoassays
-
Becton, Dickinson and Company (BD)
-
Cytology
-
Flow Cytometry
-
Licensing
-
Bio-Rad Laboratories, Inc.
-
Immunoassays
-
Liquid Biopsy
-
Droplet Digital PCR
-
Biocartis
-
Biocept, Inc.
-
Biodesix
-
bioMérieux Inc.
-
BioReference Laboratories
-
Biotheranostics, Inc. (Hologic)
-
Danaher Corporation
-
DiaSorin S.p.A
-
Immunoassays
-
Molecular Oncology
-
Enzo Biochem Inc.
-
Epic Sciences
-
Epigenomics AG
-
Exact Sciences Corp.
-
Exosome Diagnostics, Inc.
-
Foundation Medicine, Inc.
-
Guardant Health, Inc.
-
Helomics Corporation
-
Hologic, Inc.
-
Illumina, Inc.
-
LabCorp, Laboratory Corporation of America
-
Leica Biosystems (Danaher)
-
Digital Pathology
-
Stain Reagents
-
Lab Systems
-
Sample Handling
-
Circulating Tumor Cells (CTCs)
-
Artificial Intelligence
-
LungLife AI
-
Mayo Medical Laboratories
-
MDxHealth SA
-
Menarini-Silicon Biosystems
-
Myriad Genetics, Inc.
-
Natera
-
NeoGenomics
-
OPKO Health, Inc.
-
Pacific Biosciences (PacBio)
-
QIAGEN N.V.
-
Precision Medicine / Companion Diagnostics
-
Next Generation Sequencing
-
Sample Prep, Informatics
-
Digital PCR
-
Bioinformatics
-
Liquid Biopsy
-
Cervical Cancer
-
Quest Diagnostics
-
Roche Diagnostics
-
HPV
-
Cancer Companion Testing
-
Liquid Biopsy
-
IT in Anatomical Pathology
-
Information Technology
-
Sysmex Corp.
-
Hematology
-
Coagulation
-
Urinalysis
-
Immunoassays
-
Lab Information System
-
Information Technology
-
Flow Cytometry
-
Precision Medicine / Companion Test Diagnostics
-
Liquid Biopsy
-
Exosomes
-
Oncology
-
Sysmex Inostics
-
Forging New Markets
-
Thermo Fisher Scientific Inc.
-
Oncology Companion Diagnostics
-
Liquid Biopsy
-
Trovagene, Inc. (now Cardiff Oncology)
-
Ventana Medical Systems (Roche)
-
Immunohistochemistry – IHC
-
Cervical Cancer Screening
-
Companion Diagnostics
-
Veracyte
|
The World Market for Cancer Diagnostics, 2021
1 Dec 2021
Cancer testing is maturing from personalized medicine to precision medicine, where protein and molecular biomarkers are essential for precise diagnosis, therapy selection, therapy monitoring and early detection of cancer recurrence. The World Market for Cancer Diagnostics, as well as relevant industry merger data provided by Kalorama Information, provides authoritative and complete analysis of the cancer testing industry, with expert market sizing and opportunity assessment.
Segment markets for cancer testing are comprehensively covered in Kalorama Information’s World Market for Cancer Diagnostics. The report contains detailed market data on the following IVD segments for their use in cancer diagnostics:
- Immunoassay - tumor markers
- Molecular - cancer assays
- Molecular - histology
- Molecular - HPV
- CTCs
Critical Need for Prevention Supports a Market for Innovative Diagnostic Tools
Given the unfortunate statistics of cancer in the developed world, innovation is a must. Growth rates in cancer testing tends to be higher than in other IVD fields. Diagnostic tests for effective cancer screening are obviously needed more than ever. As this report goes to print a number of significant developments are taking place in cancer follow up. New imaging tools, bioinformatics, sequencing technologies, improved histological tests are among the trends discussed in this multifaceted report. The importance of this industry is seen in the flurry of investments and financing arrangements made and the number of partnerships and purchases/mergers where one or both companies are involved in cancer diagnostics. This report contains
- Investments and Financing Agreements For Cancer Diagnostics Companies
- Selected Agreements Between Cancer Diagnostic Companies
- Selected Agreements Between Cancer Diagnostic Companies and Other Diagnostic Companies
- Selected Agreements Between Cancer Diagnostic Companies and Pharmaceutical or Biopharmaceutical Companies
- Selected Cancer Diagnostic Company Agreements with Academic or Other Non-Profit Organizations
- Selected Acquisitions of Cancer Diagnostic Companies
Complete Market and Trend Analysis
In five previous editions. Kalorama has defined the oncology testing market, based on primary research of the market with particular attention to important market trends. These trends are more important to understand than today’s numbers. Market analysis in this report covers world markets for in vitro cancer diagnostics, however the reader will find a bias toward the developed areas of the globe — N. America, Japan and Western Europe. However cancer is a growing global problem and where possible the report covers cancer testing in the more industrialized developing countries of Latin America and Asia Pacific.
The phenomenon of test personalization comes under many guises as pharmacogenomic, pharmacogenetic, companion tests, and represents one of the fastest growing segments of the market for cancer tests. It has emerged fully from research into clinical practice. Instrumentation now automates many of the sample preparation and assay steps that were formerly labor intensive. New tests are being launched all the time. Some personalized cancer tests are CE Marked and FDA-cleared and many more are in development. More and more laboratories offer complex panels of tests that help physicians evaluate disease risk and make therapeutic decisions. Government and private healthcare payers have recognized the value of new molecular tools and are agreeing to pay for them.
Unparalleled Review of Cancer Testing Competitors: Top Tier IVD Companies And Specialist Companies
This report is written from the point of view of diagnostic modalities for the detection and management of cancer and in particular solid tumors. The technology to detect cancers of the blood – lymphomas, myelomas and leukemia – is mature and well established. The routine complete blood count screens for blood cell abnormalities and is followed by bone marrow analysis and flow cytometric studies of the blood cell surface markers. These to arrive at a more specific diagnosis. As such this report does not discuss area of hematological cancer diagnosis in great detail.
The emphasis is on in vitro diagnostic tests, however a discussion of the role of diagnostics in cancer management, must include in vitro and in vivo tests. The two are inextricably linked. The same cell markers used in flow cytometry and antibodies used for immunoassays to detect elements of the immunity process are used as vectors for imaging agents to detect tumors and to monitor the extent of cancer metastasis.
In addition to extensive reviews of products on the market and in development in each segment, the report provides detailed company profiles in several sections, including the following companies:
- Abbott Diagnostics
- Agendia BV
- Agilent Technologies
- ARUP Laboratories
- Asuragen Inc.
- Beckman Coulter (Danaher)
- Becton, Dickinson and Company (BD)
- Bio-Rad Laboratories, Inc.
- Biocartis
- Biocept, Inc.
- Biodesix
- bioMérieux Inc.
- BioReference Laboratories
- Biotheranostics, Inc. (Hologic)
- Danaher Corporation
- DiaSorin S.p.A
- Enzo Biochem Inc.
- Epic Sciences
- Epigenomics AG
- Exact Sciences Corp.
- Exosome Diagnostics, Inc
- Foundation Medicine, Inc.
- Guardant Health, Inc.
- Helomics Corporation
- Hologic, Inc.
- Illumina, Inc.
- LabCorp
- Leica Biosystems (Danaher)
- LungLife AI
- Mayo Medical Laboratories
- MDxHealth SA
- Menarini-Silicon Biosystems
- Myriad Genetics, Inc.
- Natera
- NeoGenomics
- OPKO Health, Inc.
- Pacific Biosciences
- Qiagen N.V.
- Quest Diagnostics
- Roche Diagnostics
- Sysmex Corp.
- Thermo Fisher Scientific Inc.
- Trovagene, Inc.
- Ventana Medical Systems (Roche)
- Veracyte
Page Count: 340
Table of Contents
-
Chapter One: Executive Summary
-
Chapter 2: Introduction and Overview
-
Histology and Cytology
-
In Situ Hybridization (ISH)
-
Immunoassays
-
Polymerase Chain Reaction (PCR)
-
Companion Diagnostics
-
Predictive Biomarker Tests for Drug-Gene Match
-
DNA and RNA Variants
-
Molecular Diagnostics in Hereditary Cancer Diagnosis
-
Cancer Markers in Widespread Usage
-
Chapter 3: Market Trends
-
Growth in Precision Medicine, Companion Diagnostics, Related Applications
-
Pharmacodiagnostic Tests
-
Companies Offering Liquid Biopsy-based Molecular Cancer Assays
-
Liquid Biopsy-based Non-Invasive Cancer Molecular Diagnostics
-
Circulating Tumor Cell (CTC) Tests
-
Sample Collection Products
-
Exosome Sequencing
-
Next-Generation Sequencing Tests
-
Whole-Genome Sequencing
-
Exome Sequencing
-
RNA Sequencing
-
Regulatory Influences
-
Companies
-
Advanced Histology Techniques
-
Automation of Histology
-
Artificial Intelligence
-
Mass Spectrometry
-
Regulatory and Reimbursement Trends
-
Reimbursement Breakthroughs and Challenges
-
Next Generation Sequencing Coverage
-
Companion Diagnostics Seeing Development in Regulations
-
LDTs
-
Food and Drug Administration
-
Directive 98/79/EC
-
Health Canada Changes and Forecasted Action
-
International Growth Opportunities
-
Chapter 4: Market Revenues and Forecast
-
Molecular Cancer Test Regional Distribution
-
Histology and Cytology
-
Histology Regional Distribution
-
Molecular Cancer Diagnostics Segment by Technology/ Method
-
HPV Regional Distribution
-
Drivers and Challenges
-
Clinical Utility of Molecular Diagnostics
-
Technological Advancements Including NGS Adopted Incrementally
-
Chapter 5: Competitive Analysis
-
Immunoassay Competitive Trends
-
IHC Market
-
Competition in ISH
-
Molecular Cancer Diagnostics Landscape
-
HPV
-
Liquid Biopsy and CTCs
-
Recent Deals and Collaborations
-
Chapter 6: COVID-19 Impact
-
Minimal Ongoing Significant Disruptions
-
Chapter 7: Corporate Profiles
-
Abbott Diagnostics
-
Companion Testing
-
Liquid Biopsy
-
Agendia BV
-
Agilent Technologies
-
Agilent in Genomics
-
Cytogenetic Analysis
-
Sequencing
-
CRISPR
-
Flow Cytometry
-
Companion Diagnostics – Dako
-
ARUP Laboratories
-
Asuragen Inc.
-
Beckman Coulter (Danaher)
-
Immunoassays
-
Becton, Dickinson and Company (BD)
-
Cytology
-
Flow Cytometry
-
Licensing
-
Bio-Rad Laboratories, Inc.
-
Immunoassays
-
Liquid Biopsy
-
Droplet Digital PCR
-
Biocartis
-
Biocept, Inc.
-
Biodesix
-
bioMérieux Inc.
-
BioReference Laboratories
-
Biotheranostics, Inc. (Hologic)
-
Danaher Corporation
-
DiaSorin S.p.A
-
Immunoassays
-
Molecular Oncology
-
Enzo Biochem Inc.
-
Epic Sciences
-
Epigenomics AG
-
Exact Sciences Corp.
-
Exosome Diagnostics, Inc.
-
Foundation Medicine, Inc.
-
Guardant Health, Inc.
-
Helomics Corporation
-
Hologic, Inc.
-
Illumina, Inc.
-
LabCorp, Laboratory Corporation of America
-
Leica Biosystems (Danaher)
-
Digital Pathology
-
Stain Reagents
-
Lab Systems
-
Sample Handling
-
Circulating Tumor Cells (CTCs)
-
Artificial Intelligence
-
LungLife AI
-
Mayo Medical Laboratories
-
MDxHealth SA
-
Menarini-Silicon Biosystems
-
Myriad Genetics, Inc.
-
Natera
-
NeoGenomics
-
OPKO Health, Inc.
-
Pacific Biosciences (PacBio)
-
QIAGEN N.V.
-
Precision Medicine / Companion Diagnostics
-
Next Generation Sequencing
-
Sample Prep, Informatics
-
Digital PCR
-
Bioinformatics
-
Liquid Biopsy
-
Cervical Cancer
-
Quest Diagnostics
-
Roche Diagnostics
-
HPV
-
Cancer Companion Testing
-
Liquid Biopsy
-
IT in Anatomical Pathology
-
Information Technology
-
Sysmex Corp.
-
Hematology
-
Coagulation
-
Urinalysis
-
Immunoassays
-
Lab Information System
-
Information Technology
-
Flow Cytometry
-
Precision Medicine / Companion Test Diagnostics
-
Liquid Biopsy
-
Exosomes
-
Oncology
-
Sysmex Inostics
-
Forging New Markets
-
Thermo Fisher Scientific Inc.
-
Oncology Companion Diagnostics
-
Liquid Biopsy
-
Trovagene, Inc. (now Cardiff Oncology)
-
Ventana Medical Systems (Roche)
-
Immunohistochemistry – IHC
-
Cervical Cancer Screening
-
Companion Diagnostics
-
Veracyte
|
More information about this product
Other Users Also Viewed
25 Aug 2021
21-050
Kalorama Information’s latest edition of our in vitro diagnostic market report represents the fourteenth time in two decades our analysts have fully assessed the in vitro diagnostic market from scratch and re-report numbers. Last year,…
|